← FDA DRUG APPROVALS

FDA ANDA · ANDA073308

TOLMETIN SODIUM

Sponsor: ANI PHARMS

APPLICATION
ANDA073308
TYPE
ANDA
ORIGINAL APPROVAL
1992-01-24
LATEST ACTION
2024-11-21
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

TOLMETIN SODIUMDiscontinued
TOLMETIN SODIUM EQ 400MG BASE · CAPSULE · ORAL

Approval history

2024-11-21Labeling · Supplement 18 · standardAP
2021-04-28Labeling · Supplement 17 · standardAP
2016-05-09Labeling · Supplement 16 · standardAP
2016-01-27Labeling · Supplement 15 · standardAP
2002-01-23Manufacturing (CMC) · Supplement 7AP
2001-11-02Manufacturing (CMC) · Supplement 6AP
2000-07-13Manufacturing (CMC) · Supplement 5AP
2000-02-03Manufacturing (CMC) · Supplement 4AP
1996-01-18Manufacturing (CMC) · Supplement 3AP
1995-01-17Labeling · Supplement 2AP
1992-02-26Labeling · Supplement 1AP
1992-01-24OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →